NCT05613868TerminatedPhase 2
A Phase 2a Study of TPN-101 in Patients With Aicardi-Goutières Syndrome (AGS)
Transposon Therapeutics, Inc.10 sites in 3 countries4 target enrollmentStarted: March 15, 2023Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Enrollment
- 4
- Locations
- 10
- Primary Endpoint
- Change in innate immune signaling
Study Overview
Brief Summary
A phase 2a multi-center, open-label single dose level study of TPN-101 in Patients with Aicardi-Goutières Syndrome (AGS)
Detailed Description
The study is planned in pediatric and adult patients with AGS that are greater than 1 year and weigh at least 10 kg. The TPN-101 dose will be adjusted from 100 mg to 400 mg based on weight to achieve similar drug exposures in all subjects. The study plans to enroll 10 - 16 subjects. This study includes a 6-8 week Screening Period, a 48-week Open label Treatment Period, and a 12-week Follow-up Period.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Masking Description
Open label study
Eligibility Criteria
- Ages
- 12 Months to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients must meet all of the following criteria:
- •Male or female participants of the following ages:
- •Cohort 1: Adults (≥ 18 years of age)
- •Cohort 2: Adolescents (12 to 17 years of age)
- •Cohort 3: Children 5 to 11 years of age
- •Cohort 4: Children 1 to < 5 years of age and >= 10 kg in weight
- •Molecular diagnosis of AGS due to biallelic mutations in 1 of the following 5 genes: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, or SAMHD1, or due to a recognized dominant mutation in TREX1
- •IFN score in peripheral blood > 2 standard deviations above the mean score of healthy controls measured on 3 occasions, approximately 2 weeks apart, during the 6-week Screening Period.
- •Clinical syndrome consistent with AGS diagnosis based on clinical, CSF, and radiological findings. The following are examples of such findings (none of these are required for inclusion):
- •Early onset encephalopathy with psychomotor delay, spasticity, extrapyramidal signs, and microcephaly, the latter appearing in the first year of life
- •Calcifications particularly visible at basal ganglia level (putamen, pallidus, and thalamus), but also extending to the periventricular white matter
- •Cerebral white matter abnormalities
- •Cerebral atrophy
- •Important systemic symptoms in the early stages of the disease including irritability, feeding and sleeping difficulties, unexplained fevers, and the appearance of chilblain-like skin lesions on the fingers, toes, and ears
- •Has a reliable caregiver to accompany the patient to all study visits. Caregiver must have frequent contact with patient and be willing to monitor the patient's health and concomitant medications throughout the study
Exclusion Criteria
- •Mutation in IFIH1, ADAR1, LSM11, or RNU7-
- •Pre-/perinatal infections, in particular the TORCH complex (toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus)
- •Presence of other significant neurological disorders; brain tumor or other space-occupying lesion; history of severe head injury
- •Clinically significant intercurrent illness, medical condition, physical or laboratory abnormality
- •Autoimmune disease requiring treatment or management (quiescent rheumatoid arthritis, psoriasis, treated autoimmune thyroiditis, or controlled Type 1 diabetes are acceptable)
- •History of human immunodeficiency virus (HIV), hepatitis B, or any active infection during Screening
- •History of cancer within 5 years of Screening, with the exception of fully treated non-melanoma skin cancers
- •Receipt of an experimental agent within 30 days or 5 half-lives prior to Screening, whichever is longer
- •Prior treatment with an immunomodulator other than a JAK inhibitor within 6 months of Screening; patients taking JAK inhibitors for AGS must have been on a stable dose for one month prior to Screening
- •Current treatment with a nucleoside reverse transcriptase inhibitor (NRTI) or other antiviral drug
- •Receipt of systemic corticosteroids within 30 days prior to Screening
- •Any vaccination within 30 days prior to Screening
Arms & Interventions
Active, TPN-101
Experimental
100 mg/day to 400mg/ study investigational drug TPN-101 once daily for 48 weeks followed by 12 weeks of follow-up period.
Intervention: TPN-101 (Drug)
Outcomes
Primary Outcomes
Change in innate immune signaling
Time Frame: 48 weeks
Assessed by the expression of 30 interferon-stimulated genes (ISG), used to calculate an Interferon (IFN) score in whole blood
Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) of TPN-101
Time Frame: 48 weeks
Incidence and severity of spontaneously reported treatment-emergent adverse events (TEAEs) of TPN-101 administered for up to 48 weeks in patients with AGS
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (10)
Loading locations...
Similar Trials
Terminated
Phase 2
A clinical study to learn whether a new drug, TPN-101, is safe when given to AGS patientsAicardi-Goutières Syndrome (AGS)Nervous System DiseasesISRCTN15569205Transposon Therapeutics, Inc16
Completed
Phase 2
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTDAmyotrophic Lateral SclerosisFrontotemporal DementiaNCT04993755Transposon Therapeutics, Inc.42
Not yet recruiting
Not Applicable
Phase I/II study of combined treatment with AT-101, cisplatin and radiotherapy in patients with locally advanced head and neck cancerhead and neck squamous cell carcinomahead and neck cancer10027655NL-OMON33661Antoni van Leeuwenhoek Ziekenhuis50
Active, not recruiting
Not Applicable
Phase I/II Study of Combined Treatment with AT-101, Cisplatin and Radiotherapy in Patients with Locally Advanced Head and Neck CancerEUCTR2007-006120-36-NL50
Completed
Phase 2
Phase 2 Safety and Efficacy Study of AT-101 in Combination With Rituximab in Patients With Chronic Lymphocytic LeukemiaChronic Lymphocytic LeukemiaNCT00286780Ascenta Therapeutics19